MediWound (NASDAQ:MDWD) Upgraded at StockNews.com

MediWound (NASDAQ:MDWD) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued on Tuesday.

Separately, HC Wainwright restated a “buy” rating and issued a $28.00 price target on shares of MediWound in a report on Friday, March 22nd.

MediWound Trading Up 3.5 %

NASDAQ MDWD opened at $19.27 on Tuesday. MediWound has a 12 month low of $7.10 and a 12 month high of $19.86. The stock has a 50-day simple moving average of $15.80 and a 200 day simple moving average of $12.26. The company has a market capitalization of $182.87 million, a PE ratio of -25.03 and a beta of 0.93.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04. MediWound had a negative return on equity of 20.22% and a negative net margin of 35.94%. The company had revenue of $5.34 million during the quarter, compared to the consensus estimate of $5.33 million. As a group, sell-side analysts predict that MediWound will post -1.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Silverberg Bernstein Capital Management LLC grew its holdings in shares of MediWound by 7.8% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after buying an additional 6,200 shares in the last quarter. Sargent Investment Group LLC grew its holdings in shares of MediWound by 7.0% during the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 7,125 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of MediWound during the first quarter worth about $427,000. Finally, Yelin Lapidot Holdings Management Ltd. grew its holdings in shares of MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 39,348 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.